BP-C1 – Novel Cancer Drug with Low Toxicity

BP-C1, Meabco’s lead product, is an anti-neoplastic agent with palliative properties and is based on Meabco’s patented polyphenolic technology platform.

BP-C1 is positioned for the global USD 107 billion market of cancer treatment and palliation drugs. The first step is to approach the breast and pancreatic segment of this market, which accounts for 14% of all cancer types and valued at USD 12.3 billion in 2013.

BP-C1 offers a combination of immunomodulation and tumor control in one product. Usually, immunomodulation and tumor control are treated separately and by using two or more drugs.

BP-C1 has been tested in a wide range of animal trials as well as in human clinical trials together demonstrating a high safety profile together with very low toxicity. BP-C1 acts strongly apoptotic, anti-proliferative and anti-angiogenic on tumor cells, while at the same time contributing to anti-cancer immune regulatory activities.

Clinical research

BP-C1 has been tested in close to 300 breast and pancreatic cancer patients in seven countries with promising results. It is noteworthy, that more than 80% of breast cancer patients and more than 60% of pancreatic cancer patients responded to the therapy. BP-C1 is aimed at fighting the cancer combined with strengthening the body’s immune system. Our research has shown that:

  • BP-C1 had very low toxicity.
  • BP-C1 significantly reducing tumor growth.
  • BP-C1 significantly increased the quality of life.
  • BP-C1 treatment can be given as an intramuscular injection permitting treatment in a local clinic or in the patient’s own home.

Treatment of Incurable Pancreatic Cancer

In a new single center study of patients treated with BP-C1 for 32 days, 75% obtained stable disease, the quality of life improved and the toxicity was low, frequency of mainly mild side effect, and significant increased Quality of Life.

A randomized trial of BP-C1 in pancreatic cancer is well underway.

Treatment of metastatic breast cancer

The outcome of BP-C1 treatment has been investigated in several studies, most recently completed two randomized double-blinded placebo-controlled studies in metastatic breast cancer patients who have not responded to previous conventional treatments and who had limited options for further treatment. The results show that:

  • BP-C1 had a significant effect compared to placebo on tumor growth
    • Response rates, including SD, ranging from 85% to 93% (RECIST)
    • BP-C1 had the best efficacy in Triple Negative patients
  • BP-C1 had very low toxicity
  • No neutropenia or other adverse events detected
  • Only mild to moderate transient side effects
  • Quality of Life was sustained
  • Treatment was well tolerated
  • BP-C1 could be safely administered for more than 64 days
  • Treatment can easily be given in the patients’ own home or at a nearby clinic.

Clinical development plan for BP-C1 in advanced (stage 4) Metastatic Breast Cancer